Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Phase IIa Study in Asthma Patients Comparing the Efficacy and Safety of Once Daily Inhaled Interferon Beta-1a to Placebo, Administered for 14 Days After the Onset of Symptoms of an Upper Respiratory Tract Infection for the Prevention of Severe Exacerbations
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms INEXAS
- Sponsors AstraZeneca
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 27 Sep 2017 Results presented in a Synairgen media release.